In an unusual move, defendants in the GLP-1 group lawsuit have asked for a consolidation of lawsuits filed by people who have experienced blindness
Unexpectedly, the bulk of EGFR-TKI studies against TNBC are not encouraging, despite the fact that EGFR is expressed in 89% of TNBC and looks to be a viable therapeutic target (64)
Heres How GHK-Cu Supports Recovery and Longevity 1
Keep the Needle Still While the Dose Delivers After insertion, avoid moving or wiggling the needle until the injection is complete

My Approach When Prescribing Here's my general framework not a rigid protocol, but a starting point for the conversation: I Tend to Start with Semaglutide When The patient has established cardiovascular disease (because of the SELECT trial data) Insurance covers semaglutide but not tirzepatide The patient has MASH/fatty liver disease Cost is the primary concern and semaglutide is more accessible I Tend to Start with Tirzepatide When Maximum weight loss is the primary goal The patient has type 2 diabetes (tirzepatide shows greater A1C reduction roughly 2.02.5% vs 1.02.0% for semaglutide) The patient has tried semaglutide with insufficient results Insurance covers both options equally Regardless of which medication we choose, I always emphasize that GLP-1 therapy is most effective when combined with nutritional counseling, physical activity, and behavioral support

The hormonal shifts of perimenopause and menopause change everything, from how your body stores fat to how full you feel after a meal